A new tryptophan catabolic pathway is characterized from Burkholderia cepacia J2315. In this pathway, tryptophan is converted to 2-amino-3-carboxymuconate semialdehyde, which is enzymatically degraded to pyruvate and acetate via the intermediates 2-aminomuconate and 4-oxalocrotonate. This pathway differs from the proposed mammalian pathway which converts 2-aminomuconate to 2-ketoadipate and, ultimately, glutarylcoenzyme A.Tryptophan has a variety of metabolic functions within the cell. It is incorporated into the polypeptide chains of enzymes and proteins, and it is the biosynthetic precursor of the cofactor NAD (19), the antibiotics anthramycin (15) and actinomycin (16), the siderophore quinolobactin (22), and the neurotransmitters serotonin (2) and melatonin (10,29). Tryptophan can also be fully catabolized. For example, Bacillus megaterium (1) and Rhodococcus erythropolis (27) can grow with tryptophan as their sole source of carbon and nitrogen, and several pseudomonads are capable of catabolizing tryptophan (26). Eukaryotes are also capable of breaking down excess tryptophan to CO 2 , NH 3 , and H 2 O. Labeling studies indicate that tryptophan degradation in mammals takes place via the kynurenine pathway, which is also used for NAD biosynthesis in all eukaryotic organisms and in a few bacterial species (9, 21, 24) (Fig. 1). On the kynurenine pathway, the branching point between NAD biosynthesis and complete tryptophan catabolism takes place at the intermediate 2-amino-3-carboxymuconate semialdehyde (ACMS) (Fig. 1). ACMS can cyclize nonenzymatically to yield quinolinate (5), the direct precursor to the pyridine ring of NAD, or it can be enzymatically decarboxylated by ACMS decarboxylase (ACMSD) (6, 7, 28). Although the biosynthesis of NAD via the kynurenine pathway is well understood, relatively little is known about the enzymology of tryptophan catabolism after ACMS. The recent discovery of the five enzymes necessary to biosynthesize ACMS from tryptophan in several prokaryotes (17) suggests that a complete tryptophan catabolic pathway, similar to the proposed human pathway, might also exist in bacteria.To test this hypothesis, we searched for clusters of tryptophan catabolic genes in bacteria by using 3-hydroxyanthranilate-3,4-dioxygenase (HAD) (11,20,23) and ACMSD (14,23,28) sequences from the NCBI database (http://www.ncbi.nlm .nih.gov) and by using the SEED database (http://theseed .uchicago.edu/FIG/index.cgi) for comparative genome analysis. Several bacteria that contained likely gene candidates for further degradation of ACMS clustered with HAD and ACMSD were identified. In Burkholderia cepacia J2315, HAD and ACMSD orthologs occurred in a cluster with genes of unknown function. Sequence analysis suggested that one of the unknown genes might function as a 2-aminomuconate semialdehyde dehydrogenase (AMDH; EC 1.2.1.32) (12) and another as a 2-aminomuconate deaminase (AMD; EC 3.5.99.5) (13,14).A second related genomic cluster was identified immediately upstream of the HAD-AMD cluster (Fig. 2). Within the se...